In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
MedPage Today on MSN
First Drug for Deadly Transplant Complication Gets FDA's Blessing
The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...
Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...
Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...
YARTEMLEA is approved by the U.S. FDA for the treatment of TA-TMA in adults and in children ages two years and older. A marketing authorization application for YARTEMLEA for TA-TMA is under review by ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
MedPage Today on MSN
FcRn Blockers Vie to Become First Approved Drug for Sjogren's Disease
FcRn blockers are approved for other indications: efgartigimod for adults with generalized myasthenia gravis and in ...
Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.
Molecular discoveries may help improve treatments for labor and pain. When labor starts, the uterus must produce steady, precisely timed contractions to allow a safe delivery. Hormones such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback